Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB Gesundheitsforschung Lübeck. Velocity’s growth is accelerating across Europe, with 17 locations … Read more
Velocity has made an incredible impact over the past year! Our sites conducted clinical trials that supported 12 U.S. product approvals in 2023, contributing to the betterment of global health. To date, Velocity has contributed to research programs for over 50 product approvals. From pioneering vaccines to cutting-edge drugs, Velocity’s team worldwide has worked diligently … Read more
Velocity Clinical Research is committed to inclusivity and ensuring that everyone, regardless of their nationality or spoken language, can participate in groundbreaking clinical research studies. Language should never be a barrier to advancing medicine, and so, in collaboration with Boostlingo, we offer live phone and video interpretation services in over 300 languages. This includes American … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by the company in Poland by year’s end. In addition to being … Read more
Julio Rosenstock, MD, FACE, joined the American Diabetes Association’s Diabetes Core Update podcast to discuss propound results from a recently published JAMA article, “Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes.” The study indicated that once weekly tirzepatide with insulin glargine may have the potential to change the standard of care … Read more
“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. “I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. She’s been involved in several … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of an article recently published in the New England Journal of Medicine. The article highlights the results of a Phase 3 trial of elafibranor for the treatment primary biliary cholangitis, an autoimmune disease that causes inflammation and damage of the bile ducts in the … Read more
Velocity is proud to announce the MASH Council to Accelerate Research Excellence (CARE). Led by Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, the MASH CARE Council will help drive world-class operational, recruitment, and trial conduct oversight for the 20+ Velocity sites conducting liver disease research — including both metabolic dysfunction-associated … Read more
Paul Evans was recently named CEO of the Year in the Middle Market Division by Business North Carolina! He, along with his fellow awardees in the Enterprise and Growth categories, were celebrated last month at the annual CEO Summit. Since moving to North Carolina in 2018, Paul has led Velocity to achieve dramatic growth. This … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was the lead author of an article recently published in The Lancet Gastroenterology & Hepatology. Dr. Kowdley and team conducted a Phase 2 trial investigating the efficacy of rusfertide in treating HFE-related haemochromatosis (an inherited iron overload disorder caused by insufficient hepcidin production). Rusfertide prevented iron re-accumulation in … Read more